This activity is expired and is no longer available for CME credit.


Clinical Advances in Hepatocellular Carcinoma Management – Rapid Response from Chicago

Author(s)/Faculty: Richard S. Finn, MD; Joseph M. Llovet, MD; Andrew X. Zhu, MD, PhD
Release Date: 6/11/2019Expiration Date: 6/10/2020
Credit Type: CMENumber of Credits: 0
Content Type: VideoProvider:
Hepatocellular carcinoma (HCC) is an aggressive tumor that is commonly diagnosed late in the course of the disease. Several new therapies have been recently approved by the United States Food and Drug Administration that have shown promise for the enhancement of outcomes in patients with newly diagnosed and treatment-resistant HCC. As findings from pivotal clinical studies continue to evolve, and are being presented during international scientific meetings, it is imperative that all health care professionals who manage patients with HCC are afforded access to these advances. Within this CME activity, experts in the field will evaluate the latest evidence for the management of patients with HCC and discuss its implications for clinical practice; they will also review the unique array of toxicities associated with newer therapies and provide insight for their management.